AfPA Biologics Summit Highlights Need for Patient Safety, Informed Physicians
The Food and Drug Administration’s role is to determine a follow-on drug’s biosimilarity to its biologic predecessor, explained FDA’s Steven Kozlowski, MD, at Tuesday’s National Policy & Advocacy Summit on Biologics and Biosimilars.
